Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FOLD Amicus Therapeutics	$6.08 -0.2%	$7.71	$5.82 ▼ $12.65	$1.87B	0.64	2.76 million shs	9.23 million shs
LGND Ligand Pharmaceuticals	$102.51 -2.9%	$106.81	$77.43 ▼ $129.90	$1.98B	0.87	118,725 shs	169,961 shs
MNKD MannKind	$4.64 -4.4%	$4.90	$4.17 ▼ $7.63	$1.41B	1.14	2.38 million shs	2.37 million shs
RGLS Regulus Therapeutics	$7.85	$2.50	$0.83 ▼ $8.20	$520.01M	0.49	874,418 shs	696,175 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FOLD Amicus Therapeutics	-1.62%	-20.70%	-14.83%	-38.05%	-41.55%
LGND Ligand Pharmaceuticals	+2.23%	-3.86%	+6.25%	-10.37%	+44.25%
MNKD MannKind	+1.46%	-3.77%	+3.41%	-14.16%	+8.50%
RGLS Regulus Therapeutics	+0.26%	-1.63%	+390.63%	+518.11%	+252.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FOLD Amicus Therapeutics	4.2108 of 5 stars	3.4	2.0	4.3	3.1	0.8	1.9
LGND Ligand Pharmaceuticals	4.2727 of 5 stars	3.5	0.0	4.4	3.3	2.5	1.9
MNKD MannKind	3.0406 of 5 stars	3.6	2.0	0.0	3.5	0.8	1.9
RGLS Regulus Therapeutics	1.5672 of 5 stars	2.1	5.0	0.0	2.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	166.81% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$146.43	42.84% Upside
MNKD MannKind	3.22	Buy	$9.56	106.31% Upside
RGLS Regulus Therapeutics	2.29	Hold	$8.50	8.28% Upside

Current Analyst Ratings Breakdown

Latest RGLS, LGND, FOLD, and MNKD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/2/2025	FOLD Amicus Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $22.00
5/2/2025	FOLD Amicus Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$12.00 ➝ $9.00
5/1/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$9.00
4/30/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$7.00
4/30/2025	RGLS Regulus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$28.00 ➝ $11.00
4/30/2025	RGLS Regulus Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $7.00
4/10/2025	LGND Ligand Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$143.00
4/10/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$12.00
4/9/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FOLD Amicus Therapeutics	$543.14M	3.45	N/A	N/A	$0.63 per share	9.65
LGND Ligand Pharmaceuticals	$167.13M	11.83	$4.20 per share	24.39	$40.39 per share	2.54
MNKD MannKind	$285.50M	4.93	N/A	N/A	($0.91) per share	-5.09
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FOLD Amicus Therapeutics	-$151.58M	-$0.09	N/A	14.14	1.51	-10.62%	12.44%	2.60%	N/A
LGND Ligand Pharmaceuticals	$52.15M	-$0.16	40.84	27.63	N/A	29.68%	4.95%	4.39%	5/8/2025 (Estimated)
MNKD MannKind	-$11.94M	$0.10	66.21	20.15	N/A	8.07%	-17.74%	8.68%	5/8/2025 (Estimated)
RGLS Regulus Therapeutics	-$30.04M	-$0.87	N/A	N/A	N/A	N/A	-53.07%	-48.58%	5/8/2025 (Estimated)

Latest RGLS, LGND, FOLD, and MNKD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/8/2025	Q1 2025	MNKD MannKind	$0.03	$0.04	+$0.01	$0.04	$75.86 million	$78.35 million
5/8/2025	Q1 2025	RGLS Regulus Therapeutics	-$0.33	-$0.15	+$0.18	-$0.15	N/A	N/A
3/20/2025	Q4 2024	RGLS Regulus Therapeutics	-$0.20	-$0.20	N/A	-$0.20	N/A	N/A
2/26/2025	Q4 2024	MNKD MannKind	$0.03	$0.03	N/A	$0.03	$74.99 million	$76.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FOLD Amicus Therapeutics	2.01	3.39	2.42
LGND Ligand Pharmaceuticals	N/A	12.49	11.81
MNKD MannKind	N/A	4.54	4.17
RGLS Regulus Therapeutics	N/A	14.15	14.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FOLD Amicus Therapeutics	N/A
LGND Ligand Pharmaceuticals	91.28%
MNKD MannKind	49.55%
RGLS Regulus Therapeutics	92.38%

Insider Ownership

Company	Insider Ownership
FOLD Amicus Therapeutics	2.20%
LGND Ligand Pharmaceuticals	5.90%
MNKD MannKind	2.70%
RGLS Regulus Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FOLD Amicus Therapeutics	480	307.93 million	292.23 million	Optionable
LGND Ligand Pharmaceuticals	80	19.28 million	17.78 million	Optionable
MNKD MannKind	400	303.85 million	267.51 million	Optionable
RGLS Regulus Therapeutics	30	66.24 million	62.65 million	Optionable

RGLS, LGND, FOLD, and MNKD Headlines

Recent News About These Companies

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

May 8 at 4:20 PM | prnewswire.com

What is Leerink Partnrs' Estimate for RGLS Q1 Earnings?

May 6 at 1:23 AM | marketbeat.com

Analysts Issue Forecasts for RGLS Q1 Earnings

May 6 at 1:21 AM | americanbankingnews.com

JPMorgan Chase & Co. Purchases 111,485 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)

May 5 at 3:07 AM | marketbeat.com

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

May 4, 2025 | businesswire.com

Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal

May 4, 2025 | gurufocus.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Sees Large Decline in Short Interest

May 4, 2025 | marketbeat.com

Regulus Therapeutics (NASDAQ:RGLS) Lowered to "Hold" Rating by Wells Fargo & Company

May 4, 2025 | marketbeat.com

Regulus Therapeutics (NASDAQ:RGLS) Downgraded to "Hold" Rating by Leerink Partnrs

May 4, 2025 | marketbeat.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by RA Capital Management L.P.

May 3, 2025 | marketbeat.com

Regulus Therapeutics (RGLS) Projected to Post Earnings on Thursday

May 3, 2025 | marketbeat.com

Regulus Therapeutics' (RGLS) "Hold" Rating Reiterated at Canaccord Genuity Group

May 3, 2025 | americanbankingnews.com

Regulus Therapeutics (NASDAQ:RGLS) Earns Market Perform Rating from Leerink Partners

May 3, 2025 | americanbankingnews.com

Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $8.20

May 3, 2025 | americanbankingnews.com

Wells Fargo Downgrades Regulus Therapeutics (RGLS)

May 2, 2025 | msn.com

Novartis to buy Regulus Therapeutics for as much as $1.7 billion

May 2, 2025 | latimes.com

Regulus Therapeutics (NASDAQ:RGLS) Shares Pass Above 200-Day Moving Average - Here's What Happened

May 2, 2025 | marketbeat.com

Jones Trading Downgrades Regulus Therapeutics (RGLS)

May 1, 2025 | msn.com

Novartis Acquires Regulus Therapeutics for $800 Million

May 1, 2025 | gurufocus.com

Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal

May 1, 2025 | gurufocus.com

Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements

April 30, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGLS, LGND, FOLD, and MNKD Company Descriptions

Amicus Therapeutics NASDAQ:FOLD

$6.08 -0.01 (-0.16%)

Closing price 04:00 PM Eastern

Extended Trading

$6.08 0.00 (0.00%)

As of 07:10 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ligand Pharmaceuticals NASDAQ:LGND

$102.51 -3.11 (-2.94%)

Closing price 04:00 PM Eastern

Extended Trading

$102.51 0.00 (0.00%)

As of 06:18 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

MannKind NASDAQ:MNKD

$4.64 -0.22 (-4.43%)

Closing price 03:59 PM Eastern

Extended Trading

$4.63 0.00 (-0.11%)

As of 07:51 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Regulus Therapeutics NASDAQ:RGLS

$7.85 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$7.84 0.00 (-0.06%)

As of 07:58 PM Eastern

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time